Pembrolizumab–chemotherapy was favored for PFS over placebo–chemotherapy in the ESCC and PD-L1 CPS ≥ 10 subgroups (Fig. 2b, c). The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.